Nerviano Medical Sciences S.r.l.

Pharmacia & Upjohn

Pfizer Italia S.r.l.

Pharmacia Italia S.p.a.

Anna Vulpetti

Paolo Pevarello

Maria Gabriella Brasca

Daniele Fancelli

Gabriella Traquandi

Raffaella Amici

Paolo Orsini

Achille Panzeri

Paola Vianello

Paolo Polucci

Ron Ferguson

Francesca Quartieri

Roberto D'Alessio

Fulvia Roletto

Marcella Nesi

Patrick Roussel

Fabrizio Orzi

Mario Varasi

Manuela Villa

Barbara Salom

Antonio Longo

Antonella Isacchi

Valeria Pittal&agrave;

Nicola Mongelli

Ermes Vanotti

Gianluca Mariano Enrico Papeo

Matteo D'Anello

Giovanni Cervi

Katia Martina

Cesare Gennari

Francesco Nicotra

Daniela Berta

Eduard Felder

Marzia Villa

Matteo D'anello

Roberto D'alessio

Barbara La Ferla

Mauro Riccaboni

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Compounds represented by formula (Ia) or (Ib) and wherein R and Rare as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.

Substituted pyrrolo-pyrazole derivatives as kinase inhibitors

Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors

Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

Aminoindazole derivatives active as kinase inhibitors

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

A new class of pyrazolo derivative compounds having the formula where R and Rhave the meanings given herein. The pyrazolo derivative compounds are useful in treating cell proliferative disorders caused by and/or associated with an altered cell cycle dependent kinase activity in mammals. The compounds may be provided in pharmaceutical compositions or in a kit.

Compounds which are oxazolyl-pyrazole derivatives, as defined in the specification, and pharmaceutically acceptable salts thereof; are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.

Oxazolyl-pyrazole derivatives as kinase inhibitors

Compounds which are 2-amino-1,3-thiazole derivatives of formula (I)wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from i) straight or branched C&#x2013;Calkyl, C&#x2013;Calkenyl or C&#x2013;Calkynyl; ii) C&#x2013;Ccycloalkyl; iii) aryl or arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; Ris an optionally further substituted group selected from: i) straight or branched C&#x2013;Calkyl or C&#x2013;Calkenyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain; v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain; vi) an optionally protected amino acid residue; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.

2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents

Compounds which are 2-ureido-1,3-thiazole derivatives of formula (I) wherein R is a halogen atom, a nitro group, an optionally substituted amino group or it is a group optionally further substituted, selected from: i) straight or branched C-Calkyl; ii) C-Ccycloalkyl; iii) aryl or arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; Ris an optionally substituted group selected from: i) straight or branched C-Calkyl; ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring; iii) aryl or arylcarbonyl; iv) arylalkyl with from 1 to 6 carbon atoms within the straight or branched alkyl chain; Ris hydrogen, a straight or branched C-Calkyl or C-Calkenyl or alkynyl group; or, taken together with the nitrogen atom so which they are bonded, Rand Rform a substituted or unsubstituted group selected from: i) an optionally benzocondensed or bridged 5 to 7 membered heterocycle; or ii) a 9 to 11 membered spiro-heterocyclic compound; or a pharmaceutically acceptable salt thereof; are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.

2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents

Growing community of inventors

Brugherio, Italy

Anna Vulpetti